Testosterone replacement therapy and cross-sex hormone treatment

Morito Sugimoto, Hiroaki Kurahashi, Yuko Matsumoto, Masami Watanabe, Yasutomo Nasu, Hiromi Kumon, Kazushi Ishii, Atsushi Nagai

Research output: Contribution to journalArticle

Abstract

Currently, androgen replacement therapy (ART) which is provided clinically in the field of urology is a common treatment for many of the patients with LOH syndrome or gender identity disorder (GID) Female to Male (FTM). We herein describe the current situation and the challenges regarding ART for these two diseases. ART has been provided according to LOH syndrome treatment guidelines. However, the opinion of any individual clinician and/or the patient's own adherence in continuing treatment will be seen as influencing treatment decisions at any particular moment. With regard to ART in our department, cases where ART has been judged to be effective for LOH syndrome comprised 51% of cases (23 out of 45 cases). No significant difference was showen between cases which hoped treatment continuation and didn't hope. Guidelines for correctly evaluating the response to treatment and the feasibility of providing such treatment are awaited. ART provided for GID-FTM is particular in that its therapeutic effect is expected to differ greatly from that obtained when ART is provided for LOH syndrome. Order to obtain a cessation of the expected virilization and physiology of a patient's body, the hormone dose and interval need to be carefully considered. Data accumulated in our department have demonstrated that in most patients, a sufficient therapeutic effect is obtained by the administration of 125 mg testosterone enanthate for 2 weeks, and serious adverse events have not been observed. Guidelines regarding GID androgen replacement therapy are also awaited, in particular with regard to a more detailed evaluation of its predicted therapeutic effect.

Original languageEnglish
Pages (from-to)202-206
Number of pages5
JournalNishinihon Journal of Urology
Volume77
Issue number6
Publication statusPublished - Jun 1 2015

Fingerprint

Gonadal Steroid Hormones
Testosterone
Androgens
Therapeutics
Therapeutic Uses
Guidelines
Hope
Virilism
Urology
Patient Compliance

Keywords

  • Cross-sex hormone treatment
  • Gender identity disorder
  • Hormone replacement therapy
  • Late-onset hypogonadism syndrome

ASJC Scopus subject areas

  • Urology

Cite this

Sugimoto, M., Kurahashi, H., Matsumoto, Y., Watanabe, M., Nasu, Y., Kumon, H., ... Nagai, A. (2015). Testosterone replacement therapy and cross-sex hormone treatment. Nishinihon Journal of Urology, 77(6), 202-206.

Testosterone replacement therapy and cross-sex hormone treatment. / Sugimoto, Morito; Kurahashi, Hiroaki; Matsumoto, Yuko; Watanabe, Masami; Nasu, Yasutomo; Kumon, Hiromi; Ishii, Kazushi; Nagai, Atsushi.

In: Nishinihon Journal of Urology, Vol. 77, No. 6, 01.06.2015, p. 202-206.

Research output: Contribution to journalArticle

Sugimoto, M, Kurahashi, H, Matsumoto, Y, Watanabe, M, Nasu, Y, Kumon, H, Ishii, K & Nagai, A 2015, 'Testosterone replacement therapy and cross-sex hormone treatment', Nishinihon Journal of Urology, vol. 77, no. 6, pp. 202-206.
Sugimoto M, Kurahashi H, Matsumoto Y, Watanabe M, Nasu Y, Kumon H et al. Testosterone replacement therapy and cross-sex hormone treatment. Nishinihon Journal of Urology. 2015 Jun 1;77(6):202-206.
Sugimoto, Morito ; Kurahashi, Hiroaki ; Matsumoto, Yuko ; Watanabe, Masami ; Nasu, Yasutomo ; Kumon, Hiromi ; Ishii, Kazushi ; Nagai, Atsushi. / Testosterone replacement therapy and cross-sex hormone treatment. In: Nishinihon Journal of Urology. 2015 ; Vol. 77, No. 6. pp. 202-206.
@article{fb2a397ae6a84aa69ff5c9bf78503b55,
title = "Testosterone replacement therapy and cross-sex hormone treatment",
abstract = "Currently, androgen replacement therapy (ART) which is provided clinically in the field of urology is a common treatment for many of the patients with LOH syndrome or gender identity disorder (GID) Female to Male (FTM). We herein describe the current situation and the challenges regarding ART for these two diseases. ART has been provided according to LOH syndrome treatment guidelines. However, the opinion of any individual clinician and/or the patient's own adherence in continuing treatment will be seen as influencing treatment decisions at any particular moment. With regard to ART in our department, cases where ART has been judged to be effective for LOH syndrome comprised 51{\%} of cases (23 out of 45 cases). No significant difference was showen between cases which hoped treatment continuation and didn't hope. Guidelines for correctly evaluating the response to treatment and the feasibility of providing such treatment are awaited. ART provided for GID-FTM is particular in that its therapeutic effect is expected to differ greatly from that obtained when ART is provided for LOH syndrome. Order to obtain a cessation of the expected virilization and physiology of a patient's body, the hormone dose and interval need to be carefully considered. Data accumulated in our department have demonstrated that in most patients, a sufficient therapeutic effect is obtained by the administration of 125 mg testosterone enanthate for 2 weeks, and serious adverse events have not been observed. Guidelines regarding GID androgen replacement therapy are also awaited, in particular with regard to a more detailed evaluation of its predicted therapeutic effect.",
keywords = "Cross-sex hormone treatment, Gender identity disorder, Hormone replacement therapy, Late-onset hypogonadism syndrome",
author = "Morito Sugimoto and Hiroaki Kurahashi and Yuko Matsumoto and Masami Watanabe and Yasutomo Nasu and Hiromi Kumon and Kazushi Ishii and Atsushi Nagai",
year = "2015",
month = "6",
day = "1",
language = "English",
volume = "77",
pages = "202--206",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "6",

}

TY - JOUR

T1 - Testosterone replacement therapy and cross-sex hormone treatment

AU - Sugimoto, Morito

AU - Kurahashi, Hiroaki

AU - Matsumoto, Yuko

AU - Watanabe, Masami

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Ishii, Kazushi

AU - Nagai, Atsushi

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Currently, androgen replacement therapy (ART) which is provided clinically in the field of urology is a common treatment for many of the patients with LOH syndrome or gender identity disorder (GID) Female to Male (FTM). We herein describe the current situation and the challenges regarding ART for these two diseases. ART has been provided according to LOH syndrome treatment guidelines. However, the opinion of any individual clinician and/or the patient's own adherence in continuing treatment will be seen as influencing treatment decisions at any particular moment. With regard to ART in our department, cases where ART has been judged to be effective for LOH syndrome comprised 51% of cases (23 out of 45 cases). No significant difference was showen between cases which hoped treatment continuation and didn't hope. Guidelines for correctly evaluating the response to treatment and the feasibility of providing such treatment are awaited. ART provided for GID-FTM is particular in that its therapeutic effect is expected to differ greatly from that obtained when ART is provided for LOH syndrome. Order to obtain a cessation of the expected virilization and physiology of a patient's body, the hormone dose and interval need to be carefully considered. Data accumulated in our department have demonstrated that in most patients, a sufficient therapeutic effect is obtained by the administration of 125 mg testosterone enanthate for 2 weeks, and serious adverse events have not been observed. Guidelines regarding GID androgen replacement therapy are also awaited, in particular with regard to a more detailed evaluation of its predicted therapeutic effect.

AB - Currently, androgen replacement therapy (ART) which is provided clinically in the field of urology is a common treatment for many of the patients with LOH syndrome or gender identity disorder (GID) Female to Male (FTM). We herein describe the current situation and the challenges regarding ART for these two diseases. ART has been provided according to LOH syndrome treatment guidelines. However, the opinion of any individual clinician and/or the patient's own adherence in continuing treatment will be seen as influencing treatment decisions at any particular moment. With regard to ART in our department, cases where ART has been judged to be effective for LOH syndrome comprised 51% of cases (23 out of 45 cases). No significant difference was showen between cases which hoped treatment continuation and didn't hope. Guidelines for correctly evaluating the response to treatment and the feasibility of providing such treatment are awaited. ART provided for GID-FTM is particular in that its therapeutic effect is expected to differ greatly from that obtained when ART is provided for LOH syndrome. Order to obtain a cessation of the expected virilization and physiology of a patient's body, the hormone dose and interval need to be carefully considered. Data accumulated in our department have demonstrated that in most patients, a sufficient therapeutic effect is obtained by the administration of 125 mg testosterone enanthate for 2 weeks, and serious adverse events have not been observed. Guidelines regarding GID androgen replacement therapy are also awaited, in particular with regard to a more detailed evaluation of its predicted therapeutic effect.

KW - Cross-sex hormone treatment

KW - Gender identity disorder

KW - Hormone replacement therapy

KW - Late-onset hypogonadism syndrome

UR - http://www.scopus.com/inward/record.url?scp=84936863932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936863932&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84936863932

VL - 77

SP - 202

EP - 206

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 6

ER -